Hyperuricemia in CKD : To Treat or Not To Treat

Hyperuricemia is frequently observed in patients with chronic kidney disease (CKD), yet its clinical significance and management remain areas of ongoing debate. While elevated serum uric acid has been linked to CKD progression and cardiovascular risk, consensus on whether asymptomatic hyperuricemia should be actively treated is still evolving.

This international scientific speaker program brings together global clinical perspectives to examine current evidence, guideline recommendations, and real-world practice in managing hyperuricemia in CKD. The session will explore pathophysiological insights, trial data, and practical considerations to help clinicians make informed, patient-centric decisions in daily nephrology practice.